Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
142.66B
Market cap142.66B
Price-Earnings ratio
19.18
Price-Earnings ratio19.18
Dividend yield
6.88%
Dividend yield6.88%
Average volume
36.75M
Average volume36.75M
High today
$25.18
High today$25.18
Low today
$24.67
Low today$24.67
Open price
$24.83
Open price$24.83
Volume
45.08M
Volume45.08M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.11
52 Week low$23.11

Stock Snapshot

The current Pfizer(PFE) stock price is $25.04, with a market capitalization of 142.66B. The stock trades at a price-to-earnings (P/E) ratio of 19.18 and offers a dividend yield of 6.88%.

On 2026-08-01, Pfizer(PFE) stock traded between a low of $24.67 and a high of $25.18. Shares are currently priced at $25.04, which is +1.5% above the low and -0.6% below the high.

The Pfizer(PFE)'s current trading volume is 45.08M, compared to an average daily volume of 36.75M.

During the past year, Pfizer(PFE) stock moved between $23.11 at its lowest and $28.75 at its peak.

During the past year, Pfizer(PFE) stock moved between $23.11 at its lowest and $28.75 at its peak.

PFE News

Simply Wall St 7h
Butterfly Network Stock And Other AI Healthcare Names With Real Clinical Use

AI in healthcare sits at the crossroads of powerful trends that matter for investors, from aging populations and rising treatment costs to central banks wrestli...

Butterfly Network Stock And Other AI Healthcare Names With Real Clinical Use
Nasdaq 1d
Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

Key Points Pfizer's financial results haven't been great, and upcoming patent cliffs could exacerbate the problem. However, the company's large pipeline acros...

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?
Simply Wall St 2d
LITFULO Vitiligo Win And New COVID Shot Could Be A Game Changer For Pfizer

In late July 2026, Pfizer reported positive Phase 3 results for its oral JAK3/TEC inhibitor LITFULO in nonsegmental vitiligo and secured European Commission app...

LITFULO Vitiligo Win And New COVID Shot Could Be A Game Changer For Pfizer

Analyst ratings

62%

of 29 ratings
Buy
31%
Hold
62.1%
Sell
6.9%

More PFE News

TipRanks 2d
Pfizer’s Symbiotic-Lung-10 Trial: A Fresh Lung Cancer Bet with Pipeline Upside for PFE

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Benzinga 2d
Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials

The trials demonstrated that the medication provided significant improvements for patients suffering from both active and stable forms of the condition across a...

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials
TipRanks 3d
Pfizer says LITFULO studies meet co-primary endpoints

Pfizer (PFE) announced topline results from two Phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both active and stable...

Simply Wall St 4d
Pfizer Stock Looks Fairly Valued With Strong Pipeline But Weaker Earnings

Pfizer stock sits in an awkward middle ground today. The shares have fallen about 28% over the past five years, yet recent gains and a mixed valuation score sug...

Pfizer Stock Looks Fairly Valued With Strong Pipeline But Weaker Earnings
TipRanks 4d
Pfizer Fine Tunes Ibuzatrelvir Tablet in Completed Phase 1 Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

TipRanks 5d
Pfizer: Hold Rating Reiterated as Analyst Keeps $28 Price Target Unchanged Amid Balanced Pipeline Prospects and LOE Headwinds

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Pfizer, with a price target of $28.00. Claim 55% Off TipRanks Unlo...

Simply Wall St 6d
Is Pfizer Undervalued On Its FDA Priority Review In Prostate Cancer?

Pfizer (PFE) is back in focus after the FDA accepted a Priority Review for its supplemental New Drug Application for TALZENNA plus XTANDI in metastatic castrati...

Is Pfizer Undervalued On Its FDA Priority Review In Prostate Cancer?

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.